{"organizations": [], "uuid": "5da63edc041a565292988bb4e06a94901ee02807", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-intercept-pharma-says-sumitomo-dai/brief-intercept-pharma-says-sumitomo-dainippon-pharma-enters-into-amendment-to-certain-license-agreement-idUSFWN1Q61GD", "country": "US", "domain_rank": 408, "title": "BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-17T00:33:00.000+02:00", "replies_count": 0, "uuid": "5da63edc041a565292988bb4e06a94901ee02807"}, "author": "", "url": "https://www.reuters.com/article/brief-intercept-pharma-says-sumitomo-dai/brief-intercept-pharma-says-sumitomo-dainippon-pharma-enters-into-amendment-to-certain-license-agreement-idUSFWN1Q61GD", "ord_in_thread": 0, "title": "BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement", "locations": [], "entities": {"persons": [], "locations": [{"name": "china", "sentiment": "none"}, {"name": "korea", "sentiment": "none"}], "organizations": [{"name": "brief-intercept pharma says sumitomo dainippon", "sentiment": "negative"}, {"name": "brief-intercept pharma says sumitomo dainippon pharma", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "sumitomo dainippon pharma", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "sumitomo dainippon pharma co ltd", "sentiment": "none"}, {"name": "sumitomo dainippon", "sentiment": "none"}, {"name": "sumitomo", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 16 (Reuters) - Sumitomo Dainippon Pharma Co Ltd :\n* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011\n* INTERCEPT PHARMACEUTICALS INC - UNDER AMENDMENT, SUMITOMO DAINIPPON AGREED TO RETURN RIGHTS TO DEVELOP AND COMMERCIALIZE OCA IN JAPAN AND KOREA\n* INTERCEPT PHARMA - AGREED TO FOREGO ANY FURTHER MILESTONE OR ROYALTY PAYMENTS RELATING TO DEVELOPMENT AND COMMERCIALIZATION OF OCA IN JAPAN AND KOREA\n* INTERCEPT PHARMA - SUMITOMO DAINIPPON WAIVED RIGHTS TO COUNTRY OPTION, PARTIES ADJUSTED CERTAIN MILESTONE PAYMENT OBLIGATIONS REGARDING OCA\n* INTERCEPT PHARMA - SUMITOMO MAY CHOOSE TO PAY CO MILESTONE PAYMENT OR TERMINATE DEAL IF CERTAIN CLINICAL MILESTONES IN CHINA NOT MET BY DEC 31, 2020 Source text: ( bit.ly/2octk8w ) Further company coverage:\n ", "external_links": [], "published": "2018-02-17T00:33:00.000+02:00", "crawled": "2018-02-17T00:44:38.012+02:00", "highlightTitle": ""}